Sugi Predict

Sugi Predict / Compounds / SCHEMBL102983

SCHEMBL102983

SCHEMBL102983

CCC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.83
▸ SMN1; SMN2 Q16637 4/20 0.83
▸ MAPT P10636 2/20 0.83
▸ ALDH1A1 P00352 2/20 0.83
▸ HTT P42858 2/20 0.83
▸ GAA P10253 1/20 0.83
▸ MAOB P27338 1/20 0.71
▸ NPC1 O15118 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ NR4A1 P22736 1/20 0.70
▸ NR4A2 P43354 1/20 0.70
▸ NR4A3 Q92570 1/20 0.70
▸ EGFR P00533 2/20 0.67
▸ PARP10 Q53GL7 1/20 0.66
▸ SRD5A2 P31213 1/20 0.64
▸ L3MBTL1 Q9Y468 2/20 0.62
▸ HPGD P15428 1/20 0.61
▸ HDAC3 O15379 1/20 0.61
▸ HDAC1 Q13547 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4612393 0.88 RAB9A (0.66) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL4152328 0.87 EGFR (0.72) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL2099619 0.85 RAB9A (0.78) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL10770964 0.85 MEN1 (0.71) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL1960673 0.85 NR4A1 (0.72) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL4220632 0.85 NR4A1 (0.72) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL25081212 0.84 MAOB (0.72) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL12987281 0.84 MAOB (0.71) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL10797162 0.84 MAOB (0.67) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL41220 0.83 NR4A1 (0.70) RAB9ASMN1; SMN2MAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426105-A1 Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1h-indole Divi's Laboratories Limited (IN) 2012-03-07 — — EP claimed
US-7968732-B1 Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole Divi's Laboratories, Ltd. (IN) 2011-06-28 — — US claimed
CN-119684105-A N-phenyl isatin-mediated ketone-carboxylic acid conversion reaction method 贵州医科大学 2025-03-25 — — CN disclosed
WO-2024089155-A1 HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-02 — — WO disclosed
CN-110627704-B Preparation method of bazedoxifene 艾瑞吉瑞股份公司 2024-02-23 — — CN disclosed
EP-3512842-B1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS INC (US) 2024-01-17 — — EP disclosed
EP-3512842-B1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS INC (US) 2024-01-17 — — EP disclosed
US-20230373932-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-11-23 — — US disclosed
WO-2023023531-A1 ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2023-02-23 — — WO disclosed
US-11584743-B2 Indole derivatives as estrogen receptor degraders ARVINAS OPERATIONS, INC. (US) 2023-02-21 — — US disclosed
US-11584743-B2 Indole derivatives as estrogen receptor degraders ARVINAS OPERATIONS, INC. (US) 2023-02-21 — — US disclosed
EP-0112588-A2 4-Hydroxy-alpha-ethyl benzhydroles, process for their preparation and medicines containing these compounds RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1984-07-04 — — EP disclosed
US-4377691-A Process for the preparation of 1-(4-hydroxyphenyl)-2-(4-benzylpiperidino)-1-propanol and acid-addition salts thereof KABUSHIKI KAISHA COSMOS ENTERPRISE (JP) 1983-03-22 — — US disclosed
US-4328227-A HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1982-05-04 — — US disclosed
EP-0009683-A1 Basic phenyl ethers, pharmaceutical compositions containing them and the preparation of these ethers and compositions MERCK PATENT GmbH (DE) 1980-04-16 — — EP disclosed
US-4160088-A HALOGENATION OF KETONE, ALKANOL, HYDROLYSIS GENERAL ELECTRIC COMPANY (US) 1979-07-03 — — US disclosed
US-4158094-A BLOWING AGENTS GENERAL ELECTRIC COMPANY (US) 1979-06-12 — — US disclosed
US-4097671-A 5-PHENYL-3,6-DIHYDRO-1,3,4-OXADIAZIN-2-ONE, THERMOPLASTIC POLYMER BLOWING AGENT GENERAL ELECTRIC COMPANY (US) 1978-06-27 — — US disclosed
US-4029594-A Novel liquid crystal compounds and electro-optic devices incorporating them RCA CORPORATION (US) 1977-06-14 — — US disclosed
US-3956312-A ANTISECRETORY AGENT EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1976-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584743-B2 Indole derivatives as estrogen receptor degraders ESR1, GPER1, ESR2 RAB9A 3697/4885SMN1; SMN2 4744/4885MAPT 2535/4885
US-20230373932-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF REN, PKD2, ALPI RAB9A 1525/4885SMN1; SMN2 319/4885MAPT 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.